Latest News From Pharmachem
04 March, 2014
Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer. These findings, published in the Feb. 27 online edition of the journal Gene Therapy, build on previously reported research and could lead to new treatments for cancer.
19 March, 2014
The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs
26 March, 2014
Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research. Professor Eric Gowans from the University's Discipline of Surgery, based at the Basil Hetzel Institute at the Queen Elizabeth Hospital, has submitted a patent application for what he describes as a relatively simple but effective technique to stimulate the body's immune system response, thereby helping to deliver the vaccine. Read more... Shifting evolution into reverse promises cheaper, greener way to make new drugs TUESDAY, 25 MARCH 2014 This alternative approach to creating artificial organic molecules, called bioretrosynthesis, was first proposed four years ago by Brian Bachmann, associate professor of chemistry at Vanderbilt University. Now Bachmann and a team of collaborators report that they have succeeded in using the method to produce the HIV drug didanosine. The proof of concept experiment is described in a paper published online March 23 by the journal Nature Chemical Biology. Read more... Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria MONDAY, 24 MARCH 2014 Novartis Novartis Novartis announced that the US Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is known as chronic spontaneous urticaria (CSU) outside of the US. In the US, Xolair is indicated for CIU in adults and adolescents (12 years of age and above) who remain symptomatic despite H1-antihistamine treatment. Read more... New therapeutic target discovered for Alzheimer's disease FRIDAY, 21 MARCH 2014 A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-A? peptides linked to Alzheimer's disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans. Read more... Multidisciplinary research team proposes new model for clinical trials THURSDAY, 20 MARCH 2014 Experts across academia, industry and government propose a new method for health care providers to get the right treatments to the right patients at the right time. This new approach, A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials, published in Nature Clinical Pharmacology & Therapeutics, recommends a seamless transition from controlled experiments to real-world comparative effectiveness trials. Read more... Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells WEDNESDAY, 19 MARCH 2014 The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs. Read more... Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development TUESDAY, 18 MARCH 2014 Bayer Bayer With an investment of more than 500 million Euros at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are currently in development. The investigational therapy options for hemophilia patients - a plasma protein-free rFVIII (BAY 81-8973) and a long-acting rFVIII (BAY 94-9027) - are both currently in Phase III clinical trials. Read more...
27 March, 2014
The 11th Cork Lifelong Learning Festival will take place from Monday April 7 to Sunday April 13, 2014